Acetyl-L-Carnitine pour Age-Related Cognitive Decline
C Preuves Preuves limitées issues de petites études, mais certains signaux positifs existent.Mixed results in healthy adults but more consistently positive outcomes in elderly populations with existing cognitive concerns. Used as a prescription drug in some European countries for cognitive impairment.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'braincited.com';
const params = 'ingredient\u003Dacetyl\u002Dl\u002Dcarnitine\u0026condition\u003Dcognitive\u002Ddecline';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
En conclusion
Mixed results in healthy adults but more consistently positive outcomes in elderly populations with existing cognitive concerns. Used as a prescription drug in some European countries for cognitive impairment.
Key Study Findings
Randomized Controlled Trial
Comparative study of choline alfoscerate as a combination therapy with donepezil: A mixed double-blind randomized …
Dose: None
vs: None
Outcome: Cognitive decline
Effet: None
None
Population: Alzheimer's disease patients
Systematic Review
Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update.
Dose: None
vs: None
Outcome: None
Effet: None
None
Population: None
Review
Chronic pain and adult hippocampal neurogenesis: translational implications from preclinical studies.
Dose: None
vs: None
Outcome: None
Effet: None
None
Population: Chronic pain patients (preclinical review)
Review
Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinson's disease. An integrated strategy …
Dose: None
vs: None
Outcome: None
Effet: None
None
Population: Parkinson's disease patients
Controlled Clinical Trial
Effect of mitochondrial cofactors and antioxidants supplementation on cognition in the aged canine.
Dose: mitochondrial cofactors + antioxidants
vs: control diet
Outcome: cognitive function in aged dogs
Effet: improved learning and memory
None
Population: Aged beagle dogs
Randomized Controlled Trial
n=106
Double-blind
A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in …
Dose: None
vs: placebo
Outcome: None
Effet: None
p = 0.0083
Population: Alzheimer's disease patients
Key Statistics
14
Études
1000
Participants
↑
Positive
C
Note
Referenced Papers
Medicine
2024
3 citations
Nutrients
2020
72 citations
Ageing research reviews
2017
56 citations
Journal of pain …
2017
49 citations
Effect of mitochondrial cofactors and antioxidants supplementation on cognition in the aged canine.
Other
Neurobiology of aging
2016
19 citations
Journal of Alzheimer's …
2015
112 citations
The Cochrane database …
2015
33 citations
n-3 polyunsaturated fatty acids supplementation enhances hippocampal functionality in aged mice.
Other
Frontiers in aging …
2014
111 citations
The journal of …
2010
70 citations
Nutrition research (New …
2009
65 citations
Alternative medicine review …
2008
FASEB journal : …
2007
52 citations
Acetyl-L-carnitine for dementia.
Systematic Review
The Cochrane database …
2003
94 citations
Alternative medicine review …
1999
112 citations
La Clinica terapeutica
1990
3 citations
International journal of …
1990
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Posologies couramment utilisées
- general:
- 500-2,000 mg/day
- cognitivesupport:
- 1,500-3,000 mg/day
Limite supérieure : Well-tolerated up to 3,000 mg/day
Posologies étudiées dans la recherche
| Posologie | Durée | Effet | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| mitochondrial cofactors + antioxidants | -- | Positive | -- |
| None | -- | Positive | 106 |
| None | -- | Positive | 427 |
| None | 8.0 weeks | Positive | -- |
Moment optimal de prise : Morning, on empty stomach or with meals
Safety & Side Effects
Effets indésirables signalés
- ⚠ Gastrointestinal discomfort (nausea, vomiting, diarrhea)
- ⚠ Fishy body odor
- ⚠ Restlessness or insomnia
- ⚠ Increased appetite
Interactions connues
- ● Anticoagulants (may increase bleeding risk)
- ● Thyroid medications (may enhance thyroid hormone effects)
- ● AZT (antiretroviral — may reduce neuropathy)
Apport maximal tolérable : Well-tolerated up to 3,000 mg/day
Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.
Frequently Asked Questions
Does Acetyl-L-Carnitine help with Age-Related Cognitive Decline?
Based on 14 studies with 1,000 participants, there is limited but promising evidence that Acetyl-L-Carnitine may support Age-Related Cognitive Decline management. Our evidence grade is C (Some Evidence).
How much Acetyl-L-Carnitine should I take for Age-Related Cognitive Decline?
Studies have used various dosages. A commonly studied range is 500-2,000 mg/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Acetyl-L-Carnitine?
Reported side effects may include Gastrointestinal discomfort (nausea, vomiting, diarrhea), Fishy body odor, Restlessness or insomnia, Increased appetite. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Acetyl-L-Carnitine and Age-Related Cognitive Decline?
We rate the evidence as Grade C (Some Evidence). This rating is based on 14 peer-reviewed studies with 1,000 total participants. The overall direction of effect is positive.
Related Evidence
Autres ingrédients pour Age-Related Cognitive Decline
Acetyl-L-Carnitine pour d'autres pathologies
References
- [1] Wankiun Lee et al.. Medicine (Baltimore). 2024. Comparative study of choline alfoscerate as a combination therapy with donepezil: A mixed double-blind randomized controlled and open-label observation trial. doi:10.1097/MD.0000000000038067 PubMed
- [2] Manuela Pennisi et al.. Nutrients. 2020. Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update. doi:10.3390/nu12051389 PubMed
- [3] Oliver T Phillipson. Ageing Res Rev. 2017. Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinson's disease. An integrated strategy for management. doi:10.1016/j.arr.2017.09.006 PubMed
- [4] Mariagrazia Grilli. J Pain Res. 2017. Chronic pain and adult hippocampal neurogenesis: translational implications from preclinical studies. doi:10.2147/JPR.S146399 PubMed
- [5] Shikha Snigdha et al.. Neurobiol Aging. 2016. Effect of mitochondrial cofactors and antioxidants supplementation on cognition in the aged canine. doi:10.1016/j.neurobiolaging.2015.09.015 PubMed
- [6] Ruth Remington et al.. J Alzheimers Dis. 2015. A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in Alzheimer's Disease. doi:10.3233/JAD-142499 PubMed
- [7] Nuala Livingstone et al.. Cochrane Database Syst Rev. 2015. Pharmacological interventions for cognitive decline in people with Down syndrome. doi:10.1002/14651858.CD011546.pub2 PubMed
- [8] Debora Cutuli et al.. Front Aging Neurosci. 2014. n-3 polyunsaturated fatty acids supplementation enhances hippocampal functionality in aged mice. doi:10.3389/fnagi.2014.00220 PubMed
- [9] A Chan et al.. J Nutr Health Aging. 2010. A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia. doi:10.1007/s12603-010-0054-5 PubMed
- [10] James Suchy et al.. Nutr Res. 2009. Dietary supplementation with a combination of alpha-lipoic acid, acetyl-L-carnitine, glycerophosphocoline, docosahexaenoic acid, and phosphatidylserine reduces oxidative damage to murine brain … doi:10.1016/j.nutres.2008.11.004 PubMed
- [11] Parris M Kidd. Altern Med Rev. 2008. Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. PubMed
- [12] N W Milgram et al.. FASEB J. 2007. Acetyl-L-carnitine and alpha-lipoic acid supplementation of aged beagle dogs improves learning in two landmark discrimination tests. doi:10.1096/fj.07-8531com PubMed
- [13] S Hudson et al.. Cochrane Database Syst Rev. 2003. Acetyl-L-carnitine for dementia. doi:10.1002/14651858.CD003158 PubMed
- [14] P M Kidd. Altern Med Rev. 1999. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. PubMed
- [15] M Neri et al.. Clin Ter. 1990. [Methodology of a clinical controlled study of L-acetylcarnitine]. PubMed
- [16] W M Herrmann et al.. Int J Clin Pharmacol Res. 1990. Pharmaco-electroencephalographic and clinical effects of the cholinergic substance--acetyl-L-carnitine--in patients with organic brain syndrome. PubMed
Avertissement FDA: Ces déclarations n'ont pas été évaluées par la Food and Drug Administration. Les produits et informations sur ce site ne sont pas destinés à diagnostiquer, traiter, guérir ou prévenir quelque maladie que ce soit. Les notes de preuve présentées sont basées sur notre analyse de la recherche publiée et évaluée par des pairs et ne constituent pas un avis médical. Consultez toujours votre professionnel de santé avant de commencer tout régime de compléments alimentaires.